Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
P/E ratio for Evotec SE (EVO)
P/E ratio as of 2023: -44.87
According to Evotec SE's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -44.87. At the end of 2022 the company had a P/E ratio of -15.35.
P/E ratio history for Evotec SE from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -44.87 |
| 2022 | -15.35 |
| 2021 | 32.82 |
| 2020 | 741.58 |
| 2019 | 90.45 |
| 2018 | 31.96 |
| 2017 | 81.24 |
| 2016 | 35.81 |
| 2015 | 33.25 |
| 2014 | -69.24 |
| 2013 | -17.49 |
| 2012 | 127.33 |
| 2011 | 40.23 |
| 2010 | 97.64 |
| 2009 | -5.00 |
| 2008 | -0.94 |
| 2007 | -14.74 |
| 2006 | -6.68 |
| 2005 | -3.87 |
| 2004 | -1.92 |
| 2003 | -0.14 |
| 2002 | -0.05 |
| 2001 | -0.25 |